Haematology-Oncology · Clinical trials
Follicular Lymphoma Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About follicular lymphoma — and why its trials are hard
Follicular lymphoma is the most common indolent (slow-growing) non-Hodgkin lymphoma, typically incurable but often managed for many years. Many patients with low tumor burden are observed, while treatment for symptomatic disease centers on anti-CD20 antibody therapy. Rituximab combined with chemotherapy (bendamustine or CHOP) and rituximab maintenance is standard first-line; the glycoengineered antibody obinutuzumab plus chemotherapy improved PFS over rituximab-based therapy in the GALLIUM trial. Relapsed disease has expanded options: the immunomodulator lenalidomide plus rituximab (R2), the EZH2 inhibitor tazemetostat (particularly for EZH2-mutated tumors), the CD19 CAR T-cell therapy axicabtagene ciloleucel, and the CD20xCD3 bispecific mosunetuzumab. A key prognostic concern is early progression within 24 months of frontline therapy (POD24) and histologic transformation to aggressive lymphoma, both of which portend worse outcomes. Molecular grading (grade 1-3A) and the FLIPI index guide risk stratification; overall survival now commonly exceeds 15-20 years.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Obinutuzumab (+ chemotherapy) (Gazyva) | 2017 | First-line follicular lymphoma | GALLIUM | Progression-free survival | 3-year PFS ~80% vs ~73% for rituximab-chemo (HR ~0.66) |
| Lenalidomide + rituximab (R2) (Revlimid + Rituxan) | 2019 | R/R follicular/marginal zone lymphoma | AUGMENT | Progression-free survival | Median PFS 39.4 vs 14.1 months for rituximab-placebo (HR ~0.46) |
| Tazemetostat (Tazverik) | 2020 | R/R follicular lymphoma after >=2 lines (EZH2-mutant or no options) | Phase 2 (Study E7438-G000-101) | Objective response rate | ORR ~69% in EZH2-mutant, ~34% in wild-type (accelerated approval) |
| Axicabtagene ciloleucel (Yescarta) | 2021 | R/R follicular lymphoma after >=2 lines | ZUMA-5 | Objective/complete response | ORR ~91%, CR ~60% (accelerated approval) |
| Mosunetuzumab (Lunsumio) | 2022 | R/R follicular lymphoma after >=2 lines | GO29781 | Objective/complete response | ORR ~80%, CR ~60% (accelerated approval) |
| Epcoritamab (Epkinly) | 2024 | R/R follicular lymphoma after >=2 lines | EPCORE NHL-1 | Objective/complete response | High CR rates in heavily pretreated FL (accelerated approval; label expansion) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in follicular lymphoma development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Umbralisib (PI3K/CK1-epsilon inhibitor) — UNITY-NHL | Voluntarily withdrawn from market in 2022 despite accelerated approval | Overall-survival imbalance/safety signal observed in the UNITY-CLL trial led to withdrawal across indolent lymphoma indications |
| Idelalisib / duvelisib / copanlisib (PI3K inhibitors) — Multiple (e.g., CHRONOS-3, confirmatory studies) | Accelerated approvals largely withdrawn; class fell out of favor in FL | Immune-mediated and infectious toxicities plus failure to confirm survival benefit in confirmatory trials |
| Copanlisib (+ rituximab) — CHRONOS-3 | Positive PFS but subsequent withdrawal of indication | Toxicity and evolving benefit-risk assessment for the PI3K class in indolent lymphoma |
Choosing the right endpoint
Primary endpoints that matter in follicular lymphoma trials
- Progression-free survival (PFS) — Primary registration endpoint given long natural history; used in GALLIUM and AUGMENT
- Objective response rate (ORR) — Basis for accelerated approvals of tazemetostat, axi-cel, and mosunetuzumab
- Complete response (CR) rate — Depth of remission with CAR-T and bispecifics correlates with durability
- POD24 (progression within 24 months) — Prognostic marker identifying high-risk patients with inferior survival
- Duration of response (DoR) — Important in incurable indolent disease to gauge time off treatment
How iNGENū runs follicular lymphoma trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Follicular Lymphoma clinical trials — FAQs
Is follicular lymphoma curable?
What does an EZH2 mutation mean for treatment?
What is POD24 and why does it matter?
Ready to discuss your follicular lymphoma trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal